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Abstract
Background: Sudden cardiac arrest (SCA) is the leading cause of death in the United States. The implantable
cardioverter defibrillator (ICD) is widely used as an adjunct therapy for SCA and has been proven to be
effective in terminating life-threatening arrhythmias, but the standard transvenous device is not without
complications. The development of an entirely subcutaneous ICD (S-ICD) came about as a new approach to
sudden cardiac death (SCD) prevention without the lead associated complications. The S-ICD has been
commercially available in Europe and New Zealand since 2009 and was recently approved by the U.S. Food
and Drug Administration. The purpose of this review is to evaluate the efficacy of the new entirely
subcutaneous implantable cardioverter defibrillator.
Methods: An exhaustive medical literature search was conducted using Medline-OVID, CINAHL, and Web
of Science using the keywords: ‘defibrillator, implantable’ and ‘subcutaneous.’ The additional keyword
‘efficacy’ was used with Web of Science for further specification. All relevant articles were reviewed for validity
and then assessed for quality using the GRADE system.
Results: Five observational cohort studies were included in this systematic review. One of the articles
demonstrated a direct comparison to the TV-ICD; all others focused solely on the efficacy of the S-ICD. The
studies all had similar inclusion and exclusion criteria and the patients were prognostically similar, but the
quality of evidence was limited due to the observational nature. The S-ICD showed excellent intraoperative
defibrillation testing and appropriate shock therapy for life-threatening arrhythmias. There were a number of
inappropriate shocks delivered and complications that arose due to the novelty of the device, but many of
these adverse events were completely reversible with updates to the device.
Conclusion: The entirely subcutaneous implantable cardioverter defibrillator has been demonstrated to be a
reliable alternative to the standard TV-ICD in prevention of sudden cardiac death in certain populations.
However, longer-term randomized controlled trials would be of great value in further defining the efficacy of
this new device.
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Abstract   
Background:  Sudden cardiac arrest (SCA) is the leading cause of death in the United 
States.  The implantable cardioverter defibrillator (ICD) is widely used as an adjunct 
therapy for SCA and has been proven to be effective in terminating life-threatening 
arrhythmias, but the standard transvenous device is not without complications.  The 
development of an entirely subcutaneous ICD (S-ICD) came about as a new approach to 
sudden cardiac death (SCD) prevention without the lead associated complications.  The 
S-ICD has been commercially available in Europe and New Zealand since 2009 and was 
recently approved by the U.S. Food and Drug Administration.  The purpose of this 
review is to evaluate the efficacy of the new entirely subcutaneous implantable 
cardioverter defibrillator. 
 
Methods:  An exhaustive medical literature search was conducted using Medline-OVID, 
CINAHL, and Web of Science using the keywords: ‘defibrillator, implantable’ and 
‘subcutaneous.’  The additional keyword ‘efficacy’ was used with Web of Science for 
further specification.  All relevant articles were reviewed for validity and then assessed 
for quality using the GRADE system. 
 
Results:  Five observational cohort studies were included in this systematic review.  One 
of the articles demonstrated a direct comparison to the TV-ICD; all others focused solely 
on the efficacy of the S-ICD.  The studies all had similar inclusion and exclusion criteria 
and the patients were prognostically similar, but the quality of evidence was limited due 
to the observational nature.  The S-ICD showed excellent intraoperative defibrillation 
testing and appropriate shock therapy for life-threatening arrhythmias.  There were a 
number of inappropriate shocks delivered and complications that arose due to the novelty 
of the device, but many of these adverse events were completely reversible with updates 
to the device. 
 
Conclusion:  The entirely subcutaneous implantable cardioverter defibrillator has been 
demonstrated to be a reliable alternative to the standard TV-ICD in prevention of sudden 
cardiac death in certain populations.  However, longer-term randomized controlled trials 
would be of great value in further defining the efficacy of this new device. 
 
 
Keywords:  Defibrillator, implantable; Subcutaneous; Efficacy  
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The Efficacy of the Entirely Subcutaneous Implantable Cardioverter Defibrillator 
BACKGROUND 
The approval of the new entirely subcutaneous implantable cardioverter 
defibrillator by the US Food and Drug Administration1 in September 2012 has brought a 
lot of attention to the prevention of sudden cardiac death (SCD).  Sudden cardiac arrest 
(SCA) is the leading cause of death in the United States.  According to the American 
Heart Association, an estimate of 382 800 people experience SCA each year.2 
Unfortunately, 92% of those people do not survive.3  There are many causes of SCD, 
with coronary artery disease occurring in up to 80% of the instances, followed by 
nonischemic cardiomyopathy and valvular diseases.4  There are some genetic conditions, 
such as long QT syndrome or Brugada syndrome, that account for a lesser percentage of 
SCD.  Often, the arrhythmia involved with SCD is ventricular fibrillation.  The 
implantable cardioverter defibrillator (ICD) is widely used as an adjunct therapy for SCA 
and has been proven to be effective in terminating life-threatening arrhythmias.  Results 
from a meta-analysis of 3 trials comparing ICD therapy versus amiodarone therapy for 
secondary prevention of SCD revealed a 28% reduction in the relative risk of death with 
the ICD.5  A pooled analysis of 10 primary prevention trials revealed that ICD 
implantation provides a 7.9% absolute mortality reduction in those at risk for SCD.6  
The standard ICD consists of a generator that is implanted in a pocket usually 
below the left clavicle and transvenous leads that are inserted through a vein to the right 
ventricle and additional leads may be inserted in the right atrium or left ventricle.7 
Implantation is usually performed under general anesthesia and with the use of 
fluoroscopy to verify proper positioning of leads.  As stated previously, the transvenous 
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ICD (TV-ICD) has been proven to reduce mortality due to SCD, but it is not without 
complications.  A study performed on 440 patients implanted with TV-ICDs concluded 
that 31% of patients experience complications related to their device within 4 years after 
implantation.8  Obtaining venous access can result in problems such as pneumothorax 
due to subclavian vein puncture, pericardial tamponade due to lead perforation, or 
thrombosis of the brachial, subclavian, or jugular veins.  The study by Alter et al8 noted 
these perioperative venous complications in 2.2% of the patients.  Implantation of the 
device has a 1-2% chance of infection requiring surgical explantation.7  The concern is 
that due to the direct connection of the leads to the heart, device infection can lead to 
endocarditis.  In a study by Athan et al,9 endocarditis due to infection of cardiac device 
(pacemaker or ICD) occurred in 6.4% of their 2760 patients.  Another known 
complication related to TV-ICDs are lead related problems, such as lead dislodgement, 
lead fracture, or lead insulation defects, all of which can lead to inappropriate shock 
delivery.  Alter et al8 noted lead related complications in 52 of the 440 patients (12%).  
Another study by Daubert et al10 analyzed the frequency and outcome of inappropriate 
shocks of patients in the Multicenter Automatic Defibrillator Implantation Trial 
(MADIT) II.  Daubert et al10 study revealed that one or more inappropriate shocks 
occurred in 11.5% of the total 719 MADIT II patients and were associated with a greater 
risk of all-cause mortality.  Besides the obvious negative implications all of the 
mentioned complications have on the patient’s health, they also present a significant 
financial burden due to increased length of stay postoperatively or additional hospital 
visits.11  
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The development of an entirely subcutaneous implantable cardioverter 
defibrillator (S-ICD) came about as a new approach to SCD prevention without the lead 
associated complications.  Cameron Health Incorporated of San Clemente, California 
manufactures the S-ICD that recently passed FDA approval.  It should be known that the 
S-ICD system has been commercially available in Europe and New Zealand since 2009 
and has not been recalled for any reason.12  The device consists of a subcutaneous pulse 
generator that is placed in the area of the left 5th and 6th intercostal spaces between the 
midaxillary and anterior axillary lines.13  The generator is connected to an electrode that 
runs to the xiphoid and then vertically along the sternal border and is inserted in the 
subcutaneous tissue via 2 parasternal incisions (Figure 1). The implantation of the S-ICD 
can be performed using anatomic landmarks only, which eliminates the need for 
fluoroscopy thus reducing radiation exposure to the patient and physician.  Boston 
Scientific, the company that acquired Cameron Health and the S-ICD system, claims on 
their website that some of the main benefits to the S-ICD is that there is no risk of 
vascular injury, there is a great reduction in the likelihood of systemic infections, and as 
stated, a reduction in radiation exposure due to the implantation technique without 
fluoroscopy.14  Due to the preservation of venous access, this device may be very 
beneficial for those with long-term indications, such as younger patients with 
channelopathies or cardiomyopathies, which is also the population that is likely to be 
more active and at risk for lead fractures with TV-ICDs.  The S-ICD is contraindicated in 
patients in whom pacing is indicated, such as those with symptomatic bradycardia, 
persistent ventricular tachycardia (VT), or documented VT that is reliably terminated by 
anti-tachycardic pacing, as the S-ICD does not have pacing capabilities.12 
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According to a large nationwide survey performed in 2009, over 300 000 TV-
ICDs were implanted in a single year.15  The authors compared those numbers to a survey 
done in 2005, which revealed that there has been a significant rise in this number in 
almost every country surveyed, with the largest implanter being the United States.15  The 
S-ICD offers an alternative approach to SCD prevention without the lead associated 
complications.  However, will the new entirely subcutaneous implantable cardioverter 
defibrillator prove to be efficacious? 
METHODS 
An exhaustive medical literature search was conducted using Medline-OVID, 
CINAHL, and Web of Science using the keywords: ‘defibrillator, implantable’ and 
‘subcutaneous.’  The additional keyword ‘efficacy’ was used with Web of Science for 
further specification.  The bibliographies of the articles were searched further for relevant 
sources.  The titles and abstracts were screened for relevance and then full text articles 
with primary data evaluating the efficacy of S-ICD were formally reviewed.  Articles 
were excluded if they were noted to be commentaries, had a population of children only, 
or if the study used a different configuration than the standard (i.e. right parasternal 
location).  A search on the National Institute of Health was also conducted to reveal 
information of ongoing clinical trials.   
All relevant articles were reviewed for validity using a standard critical appraisal 
form.  The articles were then assessed using the Grades of Recommendation, 
Assessment, Development and Evaluation (GRADE) system to analyze any methodology 
limitations, inconsistent results, indirectness of evidence, publication bias, or lack of 
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precision.16  The GRADE criterion was then applied to rate the overall quality of the 
study as high, moderate, low, or very low. 
RESULTS 
The initial search on the three previously mentioned databases revealed a total of 
174 articles for review.  Articles were screened for relevancy and primary data evaluating 
the efficacy of S-ICD.  After screening, a total of 5 articles met inclusion criteria.  The 
articles were all observational cohort studies, as there are no randomized controlled trials 
to date (see Table I).  One of the articles demonstrated a direct comparison to the TV-
ICD; all others focused solely on the efficacy of the S-ICD.  All studies had the same 
general eligibility criteria for enrollment into the study.  Inclusion criteria for all studies 
was Class I, IIa, or IIb ICD indications according to the current published guidelines at 
the time of the study.  Patients were excluded from the studies if they required 
antibradycardic pacing, had a history of frequent VT, or documented VT that is reliably 
terminated by pacing, as the S-ICD does not have pacing capabilities.  Any additional, 
study specific, inclusion or exclusion criteria are stated accordingly below.   
Gold et al17 conducted the Subcutaneous versus Transvenous Arrhythmia 
Recognition Testing (START) study involving 64 patients that were implanted with the 
S-ICD in various centers.  This study assessed the ability of S-ICD to accurately diagnose 
induced shockable versus nonshockable rhythms in comparison to 3 versions of single 
and dual chamber TV-ICDs.  Baseline patient characteristics are displayed in Table II. 
The results of the Gold et al study17 revealed a sensitivity of 100% in the S-ICD’s 
detection of induced tachyarrhythmias and a specificity of 98% in the response to 
ventricular and atrial arrhythmias.  The S-ICD misclassified one of the induced atrial 
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arrhythmias.  The authors listed the individual sensitivity and specificity values for each 
TV-ICD, but overall TV-ICDs had a sensitivity of >99% and specificity of 76.7%.  No 
follow up data was collected in this study, so it was assumed that the devices respond to 
spontaneous arrhythmias in the same way as induced arrhythmias. 
Bardy et al18 conducted a clinical trial in New Zealand and Europe to evaluate the 
efficacy of the S-ICD.  They specifically looked at the ability of the device to detect 
induced rhythms at implantation and then at a 10 month follow up, they analyzed the 
device’s ability to detect and appropriately respond to spontaneous arrhythmias and also 
any complications such as infection, lead problems, and inappropriate sensing.  The study 
consisted of 55 patients that were implanted with the S-ICD between the dates of 
December 2008 and February 2009.  Participants had to meet the above inclusion and 
exclusion criteria with the addition of being excluded if they had a history of VT at rates 
less than 170 beats per minute or an estimated glomerular filtration rate less than 30 ml 
per minute.  Baseline patient characteristics are displayed in Table II.   
The results of the study by Bardy et al18 revealed 100% detection of induced 
tachyarrhythmias and 98% successful conversion of 2 consecutive induced 
tachyarrhythmias.  Two patients were eliminated from this initial portion of the study 
because defibrillation testing was not possible.  One of the 53 patients had successful 
conversion of the 1st rhythm, but the 2nd induced rhythm failed to convert to sinus 
rhythm.  This patient ultimately received a TV-ICD per protocol.  At the 10-month follow 
up, one patient died from renal failure, therefore the follow up data was based upon 54 
patients.  Three patients had a total of 12 episodes of spontaneous VT and 100% of these 
were treated successfully.  Zero patients experienced inappropriate shocks.  Pocket 
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infection occurred in 2 patients, requiring pocket revision in one, while the other opted 
for discontinuation of ICD therapy.  Lead migration or dislodgement occurred in 6 
patients, requiring lead repositioning in 4.   Oversensing or inappropriate sensing 
occurred in 4 patients, which was corrected by reprogramming the sensing vector and did 
not require surgery.  Overall, the authors felt that the S-ICD was able to detect and treat 
induced and spontaneous arrhythmias successfully and that the complications that arose 
in this early study have been corrected now by modifications in the S-ICD system.  They 
admit that further testing needs to be performed to analyze long-term benefits and 
complications, especially in comparison to the TV-ICD with large, randomized, 
multicenter, prospective clinical trials. 
Dabiri et al19 performed a single center observational study of 31 patients in the 
Netherlands that assessed any surgical problems (lead migration, infection), inappropriate 
shocks, and the accuracy of detection and response to induced and spontaneous 
arrhythmias.  Of note, the first 11 patients were included in the study above by Bardy et 
al.18  Baseline patient characteristics are displayed in Table II.  
The study by Dabiri et al19 revealed 100% detection and conversion of induced 
tachyarrhythmias upon implantation of the S-ICD.  Four patients had a total of 30 
episodes of ventricular arrhythmias, which resulted in 100% successful treatment.  Five 
patients had a total of 20 inappropriate shocks.  Three episodes occurred in 2 patients due 
to myopotentials, which was corrected with lead repositioning in one and software 
upgrade in other.  One episode occurred in one patient due to T-wave oversensing while 
coughing and another episode occurred in one patient due to double counting, both of 
which were corrected by selecting an alternate sensing vector. One patient was shocked 
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inappropriately 15 times due to T-wave oversensing after a newly developed right bundle 
branch block.  This was corrected by making a new template according to the patient’s 
new electrocardiogram.  Pocket infection occurred in one patient, however this patient 
had a known high infection risk but the device was deemed the best option despite the 
risk. Lead dislodgement occurred in 2 of the first 15 patients implanted, which was 
corrected by addition of an electrode suture sleeve at xyphoid level, which is now 
standard protocol.   
Recall that 11 patients in the Dabiri et al study19 were also included in the Bardy 
et al study18 and without specific participant data, it is impossible to definitively discern 
which results overlap.  The results of this study are limited by non-randomization and 
short, variable follow up, ranging from 30-638 days.  Overall, the authors felt that the 
study revealed complications of the S-ICD that were largely reversible and that it proved 
reasonable efficacy for the given time frame.  They agreed that larger, long-term trials 
would be beneficial. 
Olde et al20 conducted a large multicenter retrospective study of 118 Dutch 
patients that were implanted with a S-ICD between the dates of December 2008 and April 
2011.  Of note, 40 patients were previously reported in the studies by Bardy et al18 and 
Dabiri et al.19  This study assessed the detection and appropriate response of the S-ICD to 
induced and spontaneous arrhythmias, inappropriate shocks, and clinically significant 
complications that required surgical correction or hospitalization.  Baseline patient 
characteristics are displayed in Table II. 
The results of Olde et al20 revealed 100% detection and conversion of induced 
tachyarrhythmias.  There were 45 episodes of spontaneous VT that occurred in 8 patients, 
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100% of which were successfully detected and 98% were successfully treated.  One 
patient had an episode of VT that accelerated due to the shock instead of converting, 
however the rhythm spontaneously ceased with no further intervention.  There were 15 
patients that had a total of 33 inappropriate shocks.  Eleven of these episodes occurred in 
9 patients due to T-wave oversensing, which was solved by upgrading the software, 
changing the sensing vector, or making a new template during exercise testing.  Fifteen 
episodes occurred in one patient due to T-wave oversensing after a newly developed right 
bundle branch block, as mentioned above.  Another patient was inappropriately shocked 
due to excess noise sensing during transcutaneous electrical nerve stimulation therapy.  
Two episodes occurred in one patient due to atrial flutter with ventricular rates in the 
unconditional zone.  Three patients had a total of 4 episodes due to myopotential sensing 
(caused by lead migration in 2 of 3 patients).  The authors recognized that inappropriate 
shocks were more prevalent in the first 15 patients implanted per center (19% vs. 6.7%).   
Complications that arose in the Olde et al study20 consisted of pocket infection in 
7 patients, lead dislodgement in 3 patients, device dislodgment in 1 patient, skin erosion 
in 2 patients, and premature battery depletion in 2 patients.  At least 3 of the 7 patients 
with infections had predisposing factors.  All cases of lead dislodgement were corrected 
by the addition of the now standard electrode suture sleeve at xyphoid level.  As with the 
inappropriate shocks, the authors noted that these complications were more prevalent in 
the first 15 patients implanted per center (17% vs. 10%).  They speculated that these 
differences might likely be due to a learning curve of both the device and the physician 
implanting the device.  They felt that despite the adverse events that occurred, the S-ICD 
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is a reasonable alternative to the TV-ICD for certain populations but that randomized 
trials comparing the two devices would be helpful. 
Aydin et al21 conducted a multicenter trial of 40 patients in Germany that were 
implanted with the S-ICD between the dates of June 2010 and July 2011 according to the 
inclusion and exclusion criteria stated above.  This study assessed specifically shock 
efficacy (successful termination of arrhythmia) with a mean follow up of 229 days.  The 
authors also addressed first shock efficacy, inappropriate shocks, and briefly any peri- 
and post-operative complications (e.g. infection and lead dislocation).  Baseline patient 
characteristics are displayed in Table II.  Of note, the majority of patients met ICD 
indication criteria for secondary prevention instead of primary and the main cause of 
cardiac disease was idiopathic ventricular arrhythmias instead of ischemic 
cardiomyopathy when compared to the other studies mentioned.  The mean age of their 
participants was also younger than the other studies. 
The results of the study by Aydin et al21 revealed 98% detection and conversion 
of induced tachyarrhythmias, with 1 of 40 patients failing intraoperative defibrillation 
testing.  Subsequent heart biopsy of that patient revealed subacute myocardial 
inflammation, therefore the S-ICD was explanted and the patient received a TV-ICD.  
Interestingly, the patient failed intraoperative testing with the TV-ICD as well, testing 
was finally successful 2 weeks post-op.  In follow up of the remaining patients, only 
about 10% of participants experienced an event that tested shock efficacy.  There were 25 
episodes of spontaneous tachyarrhythmias, 21 of which were correctly identified and 
resulted in 28 shocks delivered by the S-ICD.  Overall shock efficacy was calculated to 
be 96.4% and first shock efficacy was 57.9%.  Two patients had a total of 2 inappropriate 
  17 
shocks due to incorrect identification of sinus tachycardia.  The authors concluded that 
despite successful conversion of induced rhythms, the S-ICD may still deliver ineffective 
shocks and therefore larger, long-term multicenter trials are needed to further define the 
safety and efficacy of the device.  
DISCUSSION 
The primary goal of this study is to provide a systematic review of the evidence 
thus far in the efficacy of the S-ICD system.  These five initial studies17-21 covered a 
rather diverse population, given that the studies were conducted in Germany, the 
Netherlands, New Zealand, and the United States.  It is important to note that two of the 
five studies reviewed, Bardy et al19 and Gold et al,17 have a likelihood of publication bias.  
The authors of those studies are either paid consultants or employees of Boston Scientific 
and/or Cameron Health.  This is not surprising, given the novelty of the device, but 
should still be taken into consideration. 
The FDA approval of the S-ICD in September 2012 was made based upon the 
results of these initial trials and the recent investigational device exemption (IDE) 
study,22 which is not yet published.1  According to the National Institute of Health, this 
study22 is a prospective, multicenter clinical trial conducted in U.S., Europe, and New 
Zealand.  They enrolled 330 patients between the dates of January 2010 and May 2011 
with the same inclusion and exclusion criteria as the studies reviewed in this article.  The 
purpose of the study was to evaluate the safety and efficacy of the S-ICD by measuring 
the ability of the device to convert induced VF and by analyzing the rate of complications 
in a 180-day period.   
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Dr. Martin Burke presented results of the IDE study at the Heart Rhythm Society 
conference in May 2012.23  Nine participants withdrew from the study prior to 
implantation; implantation was then attempted in 321 patients and successful in 314.  Of 
the 321 patients, the mean age of participants was 51.9 +/-15.5 and 74.1% were male.  
The mean LVEF 36% +/-16, with 79% of the participants meeting ICD criteria for 
primary prevention.  The device was effective in converting all induced tachyarrhythmias 
upon successful implantation.  During the 180-day follow up, there were a total of 78 
spontaneous episodes of tachyarrhythmias in 21 patients, all of which either 
spontaneously converted on their own or were successfully converted by the device.  
There were a total of 4 patients (1.3%) that had to undergo explantation of the device due 
to infection, but there were no cases of endocarditis or systemic blood stream infections.  
The researchers also noted that no infections requiring explantation occurred in the last 
214 patients, implying again a possible learning curve.  Inappropriate shocks occurred in 
38 patients either due to oversensing or episodes of supraventricular tachycardia in the 
unconditional zone.  The researchers felt that this rate of inappropriate shocks is 
comparable to that of the TV-ICD.  Based upon these results, the FDA approved the 
device for use in patients with ICD indications that do not require pacing therapy, with 
the stipulation that the manufacturing company must conduct a postmarket study to 
evaluate the long-term safety and efficacy of the device and to assess any differences 
among various populations.  The postmarket study will be conducted on 1616 patients 
with a 5-year follow up.1 
Overall, the S-ICD has proven to be very effective in rhythm detection and 
conversion of induced tachyarrhythmias.  The only study comparing directly to TV-ICDs 
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showed promising data in the superiority of the specificity of the S-ICD in comparison to 
TV-ICDs.17  It should be noted that that study only analyzed the response to induced 
rhythms however, not spontaneous.  One would speculate that the device would respond 
similarly regardless of the etiology of the rhythm, however one cannot be certain.  
Therefore a randomized trial assessing the sensitivity and specificity of the response to 
spontaneous tachyarrhythmias of TV-ICDs versus the S-ICD would be important.  The 
remaining studies that did assess the response to spontaneous tachyarrhythmias revealed 
that the S-ICD is very effective in both detecting and responding appropriately to life-
threatening arrhythmias.  However, longer-term studies need to be conducted in a 
randomized controlled fashion to further define the shock efficacy in comparison to the 
TV-ICD. 
Inappropriate shock delivery, as stated previously, has been shown to be 
associated with increased risk of all-cause mortality; therefore it is crucial that the S-ICD 
be comparable, if not superior, to the TV-ICD in this regard.  At first glance, it may seem 
that the S-ICD had a high incidence of inappropriate shocks, especially considering that 
the ideal number would be zero.  However, given that these are early clinical trials on a 
novel device, many of the instances were completely reversible by tweaking the device 
with software updates or altering the sensing vector.  The investigators of the IDE study 
felt that the prevalence of inappropriate shocks with the S-ICD was comparable to that of 
the TV-ICD, however it would be very beneficial to conduct a randomized controlled 
trial assessing this incidence with a direct comparison of the two devices. 
As with inappropriate shocks, many of the device-related complications that 
occurred in the trials appeared to decrease in prevalence as the device and physician 
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experience with the device evolved.  Once again, longer-term trials will be important in 
evaluating these complications and randomized controlled trials will help determine 
whether the benefits of the S-ICD system outweigh the risks in comparison to the 
standard TV-ICD.  
CONCLUSION 
 The entirely subcutaneous implantable cardioverter defibrillator has been 
demonstrated to be a reliable alternative to the standard TV-ICD in prevention of sudden 
cardiac death in patients not requiring pacing therapy.  The early studies that were 
reviewed in this article revealed some complications that were easily reversible with 
revamping the design of either the device or the implantation procedure.  The recent 
clinical trial revealed promising data as well, however longer-term randomized controlled 
trials would be of great value in further defining the efficacy of this new entirely 
subcutaneous device in comparison to the standard transvenous ICD. 
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Table I. GRADE Profile 
 
*Note, all observational studies automatically start at “low” quality 
aAll authors are affiliated with Boston Scientific and/or Cameron Health  
bSupported by Cameron Health 
cFollow up was variable, ranging from 30-638 days.  Anything less than 180 days is inadequate. 
dFollow up was inadequate, only 10% of patients experienced an event that tested shock efficacy 
 
 
 
 
 
 
Table II. Baseline Patient Characteristics 
Study Year/Location # of Patients 
Mean age 
(years) Sex 
Mean LVEF 
(%) ICD Indication #1 Cause of Cardiac Disease 
Gold et al17 2011/multicenter (locations not 
specified) 
64 60+/-12 78% male 31+/-14 79.7% Primary Ischemic cardiomyopathy (53%) 
Bardy et al18 Dec 2008-Feb 2009/ Europe and 
New Zealand 
55 56+/-13 80% male 34+/-13 78% Primary Ischemic cardiomyopathy (67%) 
Dabiri et al19 2010/The Netherlands single center 31 53+/-16 77% male 38.8+/-15 67% Primary Ischemic cardiomyopathy (58%) 
Olde et al20 Dec 2008-Apr 2011/ The 
Netherlands multicenter 
118 50+/-14 75% male 41+/-14 60% Primary Ischemic cardiomyopathy (38%) 
Aydin et al21 June 2010-July 2011/ Germany 
multicenter 
40 42+/-15 70% male 47+-15 57.5% Secondary Idiopathic ventricular arrhythmia (30%) 
 
 
  
 Quality Assessment 
Downgrade criteria   
Design  Study Limitations Indirectness Imprecision Inconsistency Publication 
Bias 
Quality Overall 
Quality 
 
 
 
 
Observational 
Cohort* 
Gold et al17 No 
limitations 
No 
indirectness 
No 
imprecision 
No 
inconsistency 
No serious 
biasa 
Very Low  
 
 
 
Very Low 
Bardy et al18 
 
No 
limitations 
No 
indirectness 
No 
imprecision 
No 
inconsistency 
No serious 
biasb 
Very Low 
Dabiri et al19 
 
No serious 
limitationsc 
No 
indirectness 
No 
imprecision 
No 
inconsistency 
No bias Very Low 
Olde et al20 
 
No 
limitations 
No 
indirectness 
No 
imprecision 
No 
inconsistency 
No bias Low 
Aydin et al21 
 
No serious 
limitationsd 
No 
indirectness 
No 
imprecision 
No 
inconsistency 
No bias Very Low 
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Table III. Summary of Findings 
Outcome Study Results 
Intraoperative defibrillation 
testing 
Gold et al17 
S-ICD had a sensitivity of 100% in 
the detection of induced 
tachyarrhythmias and a specificity of 
98% in the response to ventricular 
and atrial arrhythmias. 
Overall TV-ICDs had sensitivity of 
>99% and specificity of 76.7%. 
Bardy et al18 100% detection of induced tachyarrhythmias; 98% successful conversion of 2 consecutive induced tachyarrhythmiasa  
Dabiri et al19 * 100% detection and conversion of induced tachyarrhythmias 
Olde et al20** 100% detection and conversion of induced tachyarrhythmias 
Aydin et al21 98% detection and conversion of induced tachyarrhythmiasb 
Appropriate shock therapy 
Bardy et al18 100% of ventricular arrhythmias were treated successfully (3 patients with a total of 12 episodes of spontaneous VT)  
Dabiri19 100% of ventricular arrhythmias were treated successfully (4 patients with a total of 30 episodes) 
Olde et al20 100% of ventricular arrhythmias were successfully detected (45 episodes in 8 patients); 98% of ventricular arrhythmias were successfully treatedc 
Aydin et al21 
21 of 25 episodes were correctly identified, resulting in 28 shocks delivered.  
Overall shock efficacy was calculated to be 96.4%, 1st shock efficacy was 
57.9% 
Inappropriate shock delivery 
Bardy et al18 0 
Dabiri et al19 5 patients had a total of 20 inappropriate shocksd 
Olde et al20 15 patients had a total of 33 inappropriate shockse 
Aydin et al21 2 patients had a total of 2 inappropriate shocks due to incorrect identification of sinus tachycardia 
Complications 
Bardy et al18 Pocket infection in 2 patients; Lead migration/dislodgement in 6 patients; Oversensing/inappropriate sensing in 4 patients 
Dabiri et al19 Pocket infection in 1 patient; Lead dislodgement in 2 patientsf 
Olde et al20 
Pocket infection in 7 patients; Lead dislodgement in 3 patients; Device 
dislodgment in 1 patient; Skin erosion in 2 patients; Premature battery 
depletion in 2 patientsg 
*Of note, the first 11 patients were included in the study above by Bardy et al18. 
**Note: 40 patients were previously reported in studies by Bardy et al and Dabiri et al. 
a1 of 53 patients had 1st rhythm successfully converted, but 2nd induced rhythm failed to convert to sinus rhythm.  This patient ultimately received a TV-
ICD per protocol. 
b1 of 40 patients failed intraoperative defibrillation testing, subsequent heart biopsy revealed subacute myocardial inflammation.  S-ICD was explanted 
and patient received TV-ICD.  TV-ICD failed intraoperative testing as well, testing was finally successful 2 weeks post-op. 
c1 patient had an episode of VT that accelerated due to the shock instead of converting, the rhythm spontaneously ceased with no further intervention 
d3 episodes in 2 patients due to myopotentials (corrected with lead repositioning in 1 and software upgrade in other); 1 episode in 1 patient due to T-wave 
oversensing while coughing, 1 episode in 1 patient due to double counting (both corrected by selecting alternate vector); 15 episodes in 1 patient due to 
T-wave oversensing after newly developed right bundle branch block (corrected by making new template according to new ECG) 
eInappropriate shocks were more prevalent in the 1st 15 patients implanted per center (19% vs 6.7%).  11 episodes in 9 patients due to Twave oversensing 
(solved by software upgrade, changing sensing vector during exercise testing, making a new template during exercise testing); 15 episodes in 1 patient 
due to T-wave oversensing after newly developed right bundle branch block (corrected by making new template according to new ECG); 1 episode in 1 
patient due to noise sensing from transcutaneous electrical nerve stimulation therapy; 2 episodes in 1 patient due to atrial flutter with ventricular rates in 
the unconditional zone; 4 episodes in 3 patients due to myopotential sensing (caused by lead migration in 2 of 3 patients) 
fInfection occurred in patient with known high infection risk (implanted device despite risk because to allow revalidation and due to intolerance of life 
vest); Lead dislodgement occurred in 2 of the 1st 15 implanted, corrected by addition of electrode suture sleeve at xyphoid level, which is now standard 
protocol. 
gComplications were more prevalent in 1st 15 patients implanted per center (17% vs 10%).  At least 3 of the 7 patients with infections had predisposing 
factors.  All cases of lead dislodgement were corrected by the addition of the now standard electrode suture sleeve at xyphoid level. 
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Figure I.  
Locations of the Components of a Subcutaneous Implantable Cardioverter–Defibrillator In Situ. 
 
The distal and proximal sensing electrodes (D and P, respectively) of the LGen-S8 device are shown, with 
the left lateral pulse generator and an 8-cm parasternal coil electrode (C). 
 
Reproduced with permission from reference [18], Copyright Massachusetts Medical Society. 
